Edition:
United States

Proteostasis Therapeutics Inc (PTI.OQ)

PTI.OQ on NASDAQ Stock Exchange Global Market

7.95USD
19 Oct 2018
Change (% chg)

$-2.40 (-23.19%)
Prev Close
$10.35
Open
$8.20
Day's High
$8.88
Day's Low
$7.71
Volume
2,685,554
Avg. Vol
305,263
52-wk High
$10.38
52-wk Low
$1.41

Latest Key Developments (Source: Significant Developments)

Proteostasis Receives FDA Fast Track Designation For Triple Combination Program In Patients With Cystic Fibrosis
Wednesday, 4 Apr 2018 06:00am EDT 

April 4 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR TRIPLE COMBINATION PROGRAM IN PATIENTS WITH CYSTIC FIBROSIS.‍FDA GRANTED FAST TRACK DESIGNATION FOR CO'S TRIPLE COMBINATION PROGRAM FOR TREATMENT OF CYSTIC FIBROSIS​.  Full Article

Proteostasis Announces Proposed Public Offering Of Common Stock
Monday, 19 Mar 2018 04:01pm EDT 

March 19 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.PROTEOSTASIS THERAPEUTICS INC - INTENDS TO OFFER 9 MILLION SHARES OF ITS COMMON STOCK IN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Proteostasis Therapeutics Expects Cash, Cash Equivalents,Short-Term Investments To Be Enough To Fund Its Operating Expenses
Wednesday, 14 Mar 2018 05:29pm EDT 

March 14 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.PROTEOSTASIS THERAPEUTICS - EXPECTS CASH, CASH EQUIVALENTS,SHORT-TERM INVESTMENTS TO BE ENOUGH TO FUND ITS OPERATING EXPENSES & CAPEX INTO EARLY 2019.PROTEOSTASIS THERAPEUTICS INC - DATA FROM PTI'S DOUBLE COMBINATION STUDY OF PTI-801 AND PTI-808 IN CF PATIENTS EXPECTED MID 2018.  Full Article

Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation For PTI-428
Monday, 12 Mar 2018 04:05pm EDT 

March 12 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS ANNOUNCES FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR PTI-428 IN CYSTIC FIBROSIS.  Full Article

Proteostasis Therapeutics Prices Public Offering Of 8 Mln Shares At $5/Share
Wednesday, 13 Dec 2017 08:30pm EST 

Dec 13 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 8.00 MILLION COMMON SHARES PRICED AT $5.00PER SHARE.  Full Article

Proteostasis Therapeutics To Sell 7 Mln Shares In Public Offering
Tuesday, 12 Dec 2017 04:01pm EST 

Dec 12 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.INTENDS TO OFFER AND SELL, 7 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Proteostasis Therapeutics Announces Positive Clinical Results From Cystic FibrosisStudies
Monday, 11 Dec 2017 04:21pm EST 

Dec 11 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS ANNOUNCES POSITIVE CLINICAL RESULTS FROM STUDIES OF PTI-428, PTI-801 AND PTI-808 IN HEALTHY VOLUNTEERS AND PATIENTS WITH CYSTIC FIBROSIS.PROTEOSTASIS THERAPEUTICS INC - 28-DAY STUDY CONTINUES TO CONFIRM SAFETY PROFILE OF PTI-428 IN THAT IT WAS GENERALLY WELL TOLERATED.PROTEOSTASIS THERAPEUTICS INC - PTI-808 WAS FOUND TO BE GENERALLY WELL TOLERATED.PROTEOSTASIS THERAPEUTICS INC - RESULTS OF PTI-428 MEET EFFICACY ENDPOINT IN 28-DAY STUDY IN CF PATIENTS ON BACKGROUND ORKAMBI.  Full Article

Proteostasis Therapeutics Q3 loss per share $0.56
Tuesday, 14 Nov 2017 05:40pm EST 

Nov 14 (Reuters) - Proteostasis Therapeutics Inc :Proteostasis Therapeutics reports third quarter 2017 results and provides CF portfolio update.Q3 revenue $1.6 million versus $1.7 million.Qtrly loss per share $0.56 ‍​.  Full Article

Proteostasis Therapeutics to prioritize resources on cystic fibrosis R&D
Tuesday, 31 Oct 2017 04:05pm EDT 

Oct 31 (Reuters) - Proteostasis Therapeutics Inc :Proteostasis Therapeutics - ‍initiated strategic prioritization to focus resources on research & development of cystic fibrosis programs, among others​.Proteostasis -‍ as part of the initiative, co is reducing headcount dedicated to research from 46% of total workforce to 34%, by eliminating 13 positions​.Proteostasis Therapeutics - ‍resulting estimated annual cost savings related to prioritization, including personnel & other operating costs, is about $3 million​.Proteostasis Therapeutics Inc - ‍expects to incur a one-time cash charge in Q4 of 2017 for severance and other related costs of $0.2 million​.Proteostasis - ‍restructuring is not anticipated to have operational impact on company's existing cf programs and its UPR program with Astellas​.  Full Article

Proteostasis Therapeutics files investigational NDA for PTI-808, cystic fibrosis potentiator
Friday, 23 Jun 2017 07:00am EDT 

June 23 (Reuters) - Proteostasis Therapeutics Inc ::Proteostasis Therapeutics files investigational new drug application for PTI-808, cystic fibrosis potentiator.Proteostasis Therapeutics Inc says proteostasis plans to initiate a phase 1 study of PTI-808 in healthy volunteers in July.Proteostasis Therapeutics Inc - by end of June, co expects to report preliminary data from mad cohorts of two different CF patient populations.  Full Article

BRIEF-Proteostasis Therapeutics Says CFO Helen Boudreau Provided Notice Of Resignation

* PROTEOSTASIS THERAPEUTICS SAYS ON MAY 2, CFO AND TREASURER, HELEN BOUDREAU, PROVIDED NOTICE OF RESIGNATION TO PURSUE ANOTHER PROFESSIONAL OPPORTUNITY